Related Experiment Video

Updated: Jul 17, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Triptolide impairs dendritic cell migration by inhibiting CCR7 and COX-2 expression through PI3-K/Akt and NF-kappaB

Qiuyan Liu1, Taoyong Chen, Guoyou Chen

  • 1Institute of Immunology and National Key Laboratory of Medical Immunology, Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, PR China.

Molecular Immunology
|January 16, 2007
PubMed

Insights

Triptolide inhibits dendritic cell (DC) migration by reducing CCR7 and prostaglandin E2 (PGE2) expression. This mechanism explains how triptolide enhances immunosuppression and tolerance, crucial for organ transplantation.

Area of Science:

  • Immunology
  • Pharmacology
  • Cell Biology

Background:

  • Dendritic cell (DC) migration to secondary lymphoid organs is essential for initiating immune responses and T cell tolerance.
  • CCR7 and prostaglandin E2 (PGE2) are key regulators of DC migration.
  • Triptolide, derived from Tripterygium Wilfordii, is known for its immunosuppressive properties and ability to prolong allograft survival.

Purpose of the Study:

  • To investigate the effect of triptolide on DC migration.
  • To elucidate the molecular mechanisms underlying triptolide's impact on DC migration, focusing on CCR7 and PGE2.
  • To explore the role of phosphatidylinositol-3 kinase (PI3-K)/Akt and NF-kappaB signaling pathways.

Main Methods:

  • In vitro studies assessing DC migration, CCR7 expression, PGE2 production, and cyclooxygenase-2 (COX-2) expression in response to lipopolysaccharide (LPS) and triptolide.
  • In vivo experiments to evaluate the effect of triptolide on DC migration into secondary lymphoid organs.
  • Analysis of PI3-K/Akt and NF-kappaB signaling pathway activation.

Main Results:

  • Triptolide significantly inhibited LPS-induced upregulation of CCR7 and PGE2 production in DCs by suppressing COX-2 expression.
  • Triptolide impaired DC migration towards CCL19/MIP-3beta in vitro.
  • Triptolide treatment led to reduced DC migration into secondary lymphoid organs in vivo.
  • Triptolide suppressed LPS-induced activation of PI3-K/Akt and NF-kappaB pathways, which correlated with decreased COX-2 and CCR7 expression.

Conclusions:

  • Triptolide inhibits DC migration by downregulating CCR7 and PGE2 expression, partly through the inhibition of COX-2.
  • The PI3-K/Akt and NF-kappaB signaling pathways are involved in triptolide's inhibitory effects on DC migration.
  • These findings provide a mechanistic basis for triptolide's immunosuppressive effects in the context of organ transplantation and tolerance induction.

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...